Orphan drugs: overcoming HTA barriers to access

09-06-17Ewan Bennett Pharmaphorum , Market Access , HTA

How can orphan drug manufacturers demonstrate value and improve access to drugs? In this first of two articles on the subject, Ewan Bennett outlines ways to achieve reimbursement in countries where health technology assessment (HTA) approval is required.

Read Ewan Bennett's full article in Pharmaphorum.

We are part of Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd.

DRG offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 1,000 employees across 17 offices in North America, Europe and Asia.

Our Company
© DRG Abacus 2020